These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 27300524)
1. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. Raizer JJ; Chandler JP; Ferrarese R; Grimm SA; Levy RM; Muro K; Rosenow J; Helenowski I; Rademaker A; Paton M; Bredel M J Neurooncol; 2016 Aug; 129(1):139-46. PubMed ID: 27300524 [TBL] [Abstract][Full Text] [Related]
2. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. Odia Y; Kreisl TN; Aregawi D; Innis EK; Fine HA J Neurooncol; 2015 Oct; 125(1):191-5. PubMed ID: 26285768 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784 [TBL] [Abstract][Full Text] [Related]
5. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983 [TBL] [Abstract][Full Text] [Related]
6. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919 [TBL] [Abstract][Full Text] [Related]
7. The effect of an adenosine A Jackson S; Weingart J; Nduom EK; Harfi TT; George RT; McAreavey D; Ye X; Anders NM; Peer C; Figg WD; Gilbert M; Rudek MA; Grossman SA Fluids Barriers CNS; 2018 Jan; 15(1):2. PubMed ID: 29332604 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577 [TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
11. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M; J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981 [TBL] [Abstract][Full Text] [Related]
12. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. Wagner L; Marschall V; Karl S; Cristofanon S; Zobel K; Deshayes K; Vucic D; Debatin KM; Fulda S Oncogene; 2013 Feb; 32(8):988-97. PubMed ID: 22469979 [TBL] [Abstract][Full Text] [Related]
13. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. Taylor JW; Parikh M; Phillips JJ; James CD; Molinaro AM; Butowski NA; Clarke JL; Oberheim-Bush NA; Chang SM; Berger MS; Prados M J Neurooncol; 2018 Nov; 140(2):477-483. PubMed ID: 30151703 [TBL] [Abstract][Full Text] [Related]
14. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Perry JR; Rizek P; Cashman R; Morrison M; Morrison T Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530 [TBL] [Abstract][Full Text] [Related]
15. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183 [TBL] [Abstract][Full Text] [Related]
17. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Terasaki M; Bouffet E; Katsuki H; Fukushima S; Shigemori M Surg Neurol; 2008 Jan; 69(1):46-50. PubMed ID: 18054615 [TBL] [Abstract][Full Text] [Related]